Marginal zone lymphoma (MZL) is a condition wherein B cells in lymphoid tissue are affected by a rare class of slow-growing non-Hodgkin lymphoma. The second most frequent indolent non-Hodgkin's lymphoma, it accounts for around 8% of non-Hodgkin lymphoma patients. Marginal zone lymphoma can be categorized into three types, namely, extranodal, splenic, and nodal. Splenic MZL (SMZL) is limited to the spleen, bone marrow, and blood, whereas extranodal MZL (EMZL) can transpire in tissues devoid of lymphoid tissue. Only lymph nodes are affected by nodal MZL (NMZL), which is the least prevalent type. The affected tissues, clinical presentation, and management of the three types vary. Moreover, its rising prevalence is anticipated to positively impact the pipeline landscape for marginal zone lymphoma drugs.
Major companies involved in the marginal zone lymphoma treatment market include Novartis Pharmaceuticals, Eli Lilly and Company and Incyte Corporation. among others.
Leading drugs currently under the pipeline include VAY736 and LOXO-305, among others.
The increasing cases of marginal zone lymphoma and the rising technological advancements are poised to positively influence the marginal zone lymphoma pipeline landscape.
The Marginal Zone Lymphoma Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into marginal zone lymphoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for marginal zone lymphoma. The marginal zone lymphoma report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The marginal zone lymphoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with marginal zone lymphoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to marginal zone lymphoma.
The pathophysiology of marginal zone lymphoma includes long-term B-cell stimulation from infection or autoimmune, which results in genetic abnormalities and B-cell receptor stimulation. Dysregulation of BCR signaling can activate the NF-κB pathway, which is essential for marginal zone lymphoma growth. Immune cross-reactions brought on by prolonged exposure to stimuli are frequently linked to extranodal marginal zone lymphoma. Chromosome translocations, proto-oncogene mutations, and changes in MALT1 and BCL10 levels are examples of genetic abnormalities that are essential for lymphomagenesis. The pathophysiology of splenic marginal zone lymphoma most likely include ongoing BCR signaling activation.
Anti-CD20 monoclonal antibodies, especially rituximab, are frequently preferred for treating marginal zone lymphoma, either in combination with chemotherapy or on its own. Because rituximab is an indolent drug, it is recommended for asymptomatic individuals to get it as a single drug. For symptomatic, advanced-stage marginal zone lymphoma, chemoimmunotherapy, such as bendamustine-rituximab (BR), is the primary line of treatment. The objective response rate among patients using the anti-CD20 monoclonal antibody therapy has shown to be around 81%. When compared to other regimens such as R with Chlorambucil and R-CVP, BR exhibits higher efficacy and safety. Further, the rising focus on the development of marginal zone lymphoma emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.
Making up around 7% of all occurrences, marginal zone lymphoma is a minor subset of non-Hodgkin lymphomas (NHL). Approximately 7,460 new diagnoses were made in the United States in 2016. The incidence of marginal zone lymphoma was 19.6 per 1,000,000 person-years, age-standardized. After nodal and splenic marginal zone lymphoma, extranodal marginal zone lymphoma is the most prevalent subtype. Men are slightly more likely to have splenic and nodal marginal zone lymphoma, and incidence rates rise with age. marginal zone lymphoma has a 5-year relative survival rate of about 89.8% in the United States.
This section of the report covers the analysis of marginal zone lymphoma drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials, with a substantial number of marginal zone lymphoma drugs undergoing clinical development.
The drug molecule categories covered under marginal zone lymphoma pipeline analysis include small molecules, biologics, peptides, and immunotherapies, among others. The marginal zone lymphoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for marginal zone lymphoma.
The EMR report for the marginal zone lymphoma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed marginal zone lymphoma assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in marginal zone lymphoma clinical trials:
Major drugs currently in the drug pipeline are as follows:
VAY736, also called Ianalumab, is a monoclonal antibody that targets the BAFF receptor. It is being developed by Novartis Pharmaceuticals and is currently under Phase I clinical development. It is under investigation as a possible treatment option for marginal zone lymphoma because it inhibits B-cell survival and proliferation by blocking the BAFF signaling pathway. VAY736 may be used to target the aberrant B-cells that contribute to the development of marginal zone lymphoma.
Eli Lilly and Company is sponsoring a clinical trial for LOXO-305, sometimes referred to as pirtobrutinib. It is a highly selective, next-generation inhibitor of Bruton's tyrosine kinase (BTK), intended to decrease BTK activity and overcome resistance shown with previous BTK inhibitors to target B-cell malignancies, particularly marginal zone lymphoma. Clinical trials are now being conducted to assess the safety and effectiveness of pirtobrutinib in the treatment of relapsed or refractory MZL and other B-cell malignancies. The study is under Phase I clinical development.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Marginal Zone Lymphoma Drug Report provides a strategic overview of the latest and future landscape of treatments for marginal zone lymphoma. it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within marginal zone lymphoma pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share